Evidence map›Paper›PMID 37408015›Full record

ReviewBMC medicine2023

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.

Olga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki and 13 more

Abstract readReview
In one paragraph

Review in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Olga SolovyevaThe Institute of Cancer Research, London, UK.ORCID 0000-0001-7828-4099
Munyaradzi DimairoClinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.ORCID 0000-0002-9311-6920
Christopher J WeirEdinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-6494-4903
Siew Wan HeeUniversity Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK.ORCID 0000-0002-0415-263X
Aude EspinasseThe Institute of Cancer Research, London, UK.ORCID 0000-0002-1271-302X
Moreno UrsinoInserm, Centre de Recherche Des Cordeliers, Sorbonne UniversitéUniversité Paris Cité, 75006, Paris, France.ORCID 0000-0002-5709-4322
Dhrusti PatelThe Institute of Cancer Research, London, UK.ORCID 0009-0001-4113-2726
Andrew KightleyPatient and Public Involvement and Engagement (PPIE) Lead, Lichfield, UK.ORCID 0000-0002-5228-3255
Sarah HughesUniversity of Birmingham, Birmingham, UK.
Thomas JakiMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1096-188X
Adrian ManderGSK, Brentford, UK.ORCID 0000-0002-0742-9040
Thomas R Jeffry EvansUniversity of Glasgow, Glasgow, UK.ORCID 0000-0002-4175-914X
Shing LeeColumbia University, Mailman School of Public Health, New York, USA.
Sally HopewellOxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.ORCID 0000-0002-6881-6984
Khadija Rerhou RantellMedicines and Healthcare Products Regulatory Agency, London, UK.ORCID 0000-0002-6747-7650
An-Wen ChanDepartment of Medicine, Women's College Research Institute, University of Toronto, Toronto, Canada.
Alun BeddingRoche Products Ltd, Welwyn Garden City, UK.
Richard StephensNCRI, London, UK.
Dawn RichardsClinical Trials Ontario, Toronto, Canada.ORCID 0000-0003-1151-0826
Lesley RobertsNCRI, London, UK.
John KirkpatrickRoche Products Ltd, Welwyn Garden City, UK.
Johann de BonoThe Institute of Cancer Research, London, UK.ORCID 0000-0002-2034-595X
Christina YapThe Institute of Cancer Research, London, UK. Christina.yap@icr.ac.uk.ORCID 0000-0002-6715-2514

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Cancer Research UK 11650Cancer Research UK 12946Cancer Research UK 18182Cancer Research UK 20409Cancer Research UK 20850Cancer Research UK 29827Cancer Research UK NACDDP-SEP22/100001Department of HealthMedical Research Council MC_UU_00002/14Medical Research Council MR/S014357/1Medical Research Council MR/T044934/1NCATS NIH HHS UL1 TR001873
6 · The paper itself

Abstract

backgroundEarly phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and completed trial reports in the SPIRIT and CONSORT guidelines, respectively. However, both guidelines and their extensions do not adequately address the characteristics of EPDF trials. Building on the SPIRIT and CONSORT checklists, the DEFINE study aims to develop international consensus-driven guidelines for EPDF trial protocols (SPIRIT-DEFINE) and reports (CONSORT-DEFINE).

methodsThe initial generation of candidate items was informed by reviewing published EPDF trial reports. The early draft items were refined further through a review of the published and grey literature, analysis of real-world examples, citation and reference searches, and expert recommendations, followed by a two-round modified Delphi process. Patient and public involvement and engagement (PPIE) was pursued concurrently with the quantitative and thematic analysis of Delphi participants' feedback.

resultsThe Delphi survey included 79 new or modified SPIRIT-DEFINE (n = 36) and CONSORT-DEFINE (n = 43) extension candidate items. In Round One, 206 interdisciplinary stakeholders from 24 countries voted and 151 stakeholders voted in Round Two. Following Round One feedback, one item for CONSORT-DEFINE was added in Round Two. Of the 80 items, 60 met the threshold for inclusion (≥ 70% of respondents voted critical: 26 SPIRIT-DEFINE, 34 CONSORT-DEFINE), with the remaining 20 items to be further discussed at the consensus meeting. The parallel PPIE work resulted in the development of an EPDF lay summary toolkit consisting of a template with guidance notes and an exemplar.

conclusionsBy detailing the development journey of the DEFINE study and the decisions undertaken, we envision that this will enhance understanding and help researchers in the development of future guidelines. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines will allow investigators to effectively address essential items that should be present in EPDF trial protocols and reports, thereby promoting transparency, comprehensiveness, and reproducibility.

trial registrationSPIRIT-DEFINE and CONSORT-DEFINE are registered with the EQUATOR Network ( https://www.equator-network.org/ ).

Indexed as

ChecklistResearch DesignConsensusHumansPractice Guidelines as TopicReproducibility of ResultsResearch Reportclinical trialsCONSORT guidelinedose findingearly phaseSPIRIT guideline

Identifiers

PMID37408015
PMCPMC10324137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.